Clinical Optometry and Evidence-Based Practice Review

0.0(0)
Studied by 0 people
call kaiCall Kai
Locked
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/27

flashcard set

Earn XP

Description and Tags

This set of vocabulary flashcards covers clinical biostatistics, study design, epidemiology of eye diseases (glaucoma, diabetic retinopathy, myopia), and key findings from major clinical trials such as ATS, OHTS, and ETDRS.

Last updated 11:21 PM on 7/30/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

28 Terms

1
New cards

Confusion Matrix

A tool used to describe the performance of a test at predicting disease and to calculate sensitivity, specificity, prevalence, PPV, NPV, and false + or - rates.

2
New cards

Sensitivity

How often a test correctly detects a positive result, calculated as True+false-+true+\frac{\text{True+}}{\text{false-} + \text{true+}}.

3
New cards

Specificity

How often a negative result is truly negative, calculated as True-false++true-\frac{\text{True-}}{\text{false+} + \text{true-}}.

4
New cards

ROC Curve (Receiver Operating Characteristics)

A graph used to determine the optimal threshold for a test and find the appropriate balance between sensitivity and specificity.

5
New cards

Validity

The ability of a test to measure what it claims to measure, often determined by comparison to a gold standard.

6
New cards

Repeatability

An assessment of the variability of results between testing occasions.

7
New cards

COR (Coefficient of Repeatability)

The size of a clinically significant change; any change smaller than this value may be due to chance.

8
New cards

Discriminative Ability

How well a test identifies individuals with and without a specific condition.

9
New cards

NNT (Number Needed to Treat)

The number of patients that must be treated to prevent one adverse outcome.

10
New cards

NNH (Number Needed to Harm)

The number of patients who receive a treatment before one patient is harmed by it.

11
New cards

Ascertainment Bias

A bias that occurs when a doctor is more likely to identify side effects in patients they perceive as getting worse.

12
New cards

Regression to the Mean

A statistical phenomenon where a measurement, such as a single high IOP reading, reflects statistical fluctuation rather than a true failure of a drug or treatment.

13
New cards

Uncorrectable Vision Impairment

The proportion of overall vision impairment that could be improved through currently available or appropriate treatment.

14
New cards

Meta-Analysis

A study that combines results from multiple independent studies to obtain a better estimate of treatment effects, increasing statistical power.

15
New cards

Randomized Controlled Trial (RCT)

A study design where participants are randomly assigned to different interventions or control groups to minimize bias and allow causal inference.

16
New cards

Hawthorne Effect

A procedural bias where patients show improvement (e.g., better lid hygiene in a dry eye trial) because they are being monitored rather than due to the medication.

17
New cards

Type I Error

A false positive where a result reaches statistical significance even though there is no actual difference between the groups.

18
New cards

Type II Error

A false negative where a result does not reach statistical significance despite there being a real difference between groups.

19
New cards

Power

The probability that the null hypothesis will be rejected during a study.

20
New cards

Bland Altman Plot

A plot used to compare two instruments and detect differences in bias (constant error), skew (error at high/low ends), and precision (variability).

21
New cards

Absolute Risk

The incidence or probability of an event occurring in a specific population under specific conditions.

22
New cards

Relative Risk

The likelihood of an event occurring in a group of people with different behaviors, physical conditions, or environmental factors.

23
New cards

AGIS (Advanced Glaucoma Intervention Study) Key Finding

Visual field progression risk was significantly reduced when IOP was maintained below 18mmHg18\,mmHg at all visits.

24
New cards

4-2-1 Rule

The criteria for Severe NPDR: $> 20$ intraretinal hemorrhages in all 4 quadrants, prominent venous beading in $2+$ quadrants, or prominent IRMA in $1+$ quadrant.

25
New cards

Metabolic Memory

A concept from the EDIC study suggesting early intensive glycemic control provides durable benefits for decades, even if control later worsens.

26
New cards

ATS (Amblyopia Treatment Studies)

A series of clinical trials by PEDIG that shifted standard of care for amblyopia from consensus-based dogma to evidence-based practice.

27
New cards

Optical Treatment (Amblyopia)

The use of refractive correction alone as initial treatment, which can resolve up to 33%33\% of anisometropic and combined-mechanism cases.

28
New cards

Pharmacological Penalization

The use of one drop of 1%1\% Atropine daily or on weekends as an effective treatment for moderate amblyopia, comparable to patching.